» Articles » PMID: 35356634

Severe Aplastic Anemia After Receiving SARS-CoV-2 Moderna MRNA Vaccination

Overview
Journal J Hematol
Specialty Hematology
Date 2022 Mar 31
PMID 35356634
Authors
Affiliations
Soon will be listed here.
Abstract

A 60-year-old male patient presented to the emergency department with complaints of easy bruising and worsening epistaxis after receiving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Moderna mRNA vaccination. He had no personal or family history of hematological conditions. He had bruises in various stages involving the upper and lower extremities. Laboratory data revealed white blood cell count of 1.2 ×10/mm, hemoglobin of 8.0 g/dL, platelet count of 1 ×10/mm, immature platelet fraction of 0.7%, absolute neutrophil count of 0 ×10/µL, lymphocytes of 1.1 ×10/µL, neutrophils of 3% and lymphocytes of 93%. He had normal liver and renal function tests. Bone marrow biopsy confirmed very severe aplastic anemia with severely hypocellular bone marrow. His platelets continued to downtrend despite platelet transfusions and steroids. He was treated with immunosuppressive therapy with cyclosporine, anti-thymocyte globulin, eltrombopag and prednisone. The patient was discharged but was readmitted to the hospital secondary to recurrent neutropenic fever and pneumonia. He had high-grade vancomycin-resistant enterococcal infection and infection leading to septic shock and succumbing to cardiac arrest. This case demonstrates the possibility of very severe aplastic anemia following SARS-CoV-2 mRNA vaccination and clinicians need to be aware of this rare but serious side effect.

Citing Articles

Aplastic Anemia in the light of the COVID-19 pandemic: infection, vaccination, and pathophysiologic mechanisms.

Cahuapaza-Gutierrez N Ann Hematol. 2024; 103(12):4989-5005.

PMID: 39441353 DOI: 10.1007/s00277-024-06052-9.


Aplastic Anemia Following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.

Cahuapaza-Gutierrez N, Campos-Escalante T Int J Hematol Oncol Stem Cell Res. 2024; 18(3):297-305.

PMID: 39257704 PMC: 11381666. DOI: 10.18502/ijhoscr.v18i3.16111.


Multidisciplinary approaches to study anaemia with special mention on aplastic anaemia (Review).

Sankar D, Oviya I Int J Mol Med. 2024; 54(5).

PMID: 39219286 PMC: 11410310. DOI: 10.3892/ijmm.2024.5419.


The mRNA-LNP vaccines - the good, the bad and the ugly?.

Igyarto B, Qin Z Front Immunol. 2024; 15:1336906.

PMID: 38390323 PMC: 10883065. DOI: 10.3389/fimmu.2024.1336906.


COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.

Kakavandi S, Hajikhani B, Azizi P, Aziziyan F, Nabi-Afjadi M, Farani M Cell Commun Signal. 2024; 22(1):126.

PMID: 38360719 PMC: 10868124. DOI: 10.1186/s12964-023-01316-9.


References
1.
Solomou E, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V . Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007; 110(5):1603-6. PMC: 1975843. DOI: 10.1182/blood-2007-01-066258. View

2.
Shah C, Lemke S, Singh V, Gentile T . Case reports of aplastic anemia after vaccine administration. Am J Hematol. 2004; 77(2):204. DOI: 10.1002/ajh.20153. View

3.
Shenoy K, Prabha Adhikari M, Chakrapani M, Shenoy D, Pillai A . Pancytopenia after recombinant hepatitis B vaccine--an Indian case report. Br J Haematol. 2001; 114(4):955. DOI: 10.1046/j.1365-2141.2001.03006-2.x. View

4.
Issaragrisil S, Kaufman D, Anderson T, Chansung K, Leaverton P, Shapiro S . The epidemiology of aplastic anemia in Thailand. Blood. 2005; 107(4):1299-307. PMC: 1895423. DOI: 10.1182/blood-2005-01-0161. View

5.
Donnini I, Scappini B, Guidi S, Longo G, Bosi A . Acquired severe aplastic anemia after H1N1 influenza virus vaccination successfully treated with allogeneic bone marrow transplantation. Ann Hematol. 2011; 91(3):475-6. DOI: 10.1007/s00277-011-1278-0. View